Moreover, AKBA treatment of prostate cancer cells increased the expression level of the CAAT/enhancer-binding protein homologous protein (CHOP) and activated the DR5 promoter reporter gene. The gene discussed is TNFRSF10B; the disease is prostate carcinoma.